Stocks and Investing
Stocks and Investing
Mon, April 10, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Serge Belanger Reiterated (VRDN) at Strong Buy and Held Target at $47 on, Apr 10th, 2023
Serge Belanger of Needham, Reiterated "Viridian Therapeutics, Inc." (VRDN) at Strong Buy and Held Target at $47 on, Apr 10th, 2023.
Serge has made no other calls on VRDN in the last 4 months.
There are 5 other peers that have a rating on VRDN. Out of the 5 peers that are also analyzing VRDN, 0 agree with Serge's Rating of Hold.
These are the ratings of the 5 analyists that currently disagree with Serge
- Alex Thompson of "Stifel" Initiated at Strong Buy and Held Target at $49 on, Thursday, March 30th, 2023
- Douglas Tsao of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $40 on, Thursday, March 9th, 2023
- Michael Higgins of "Ladenburg Thalmann" Reiterated at Strong Buy and Held Target at $40 on, Thursday, March 9th, 2023
- Thomas Smith of "SVB Leerink" Maintained at Buy with Increased Target to $45 on, Monday, January 9th, 2023
- Tiago Fauth of "Credit Suisse" Initiated at Buy and Held Target at $51 on, Friday, December 16th, 2022
Contributing Sources